Please login to the form below

Not currently logged in
Email:
Password:

methotrexate

This page shows the latest methotrexate news and features for those working in and with pharma, biotech and healthcare.

AbbVie’s upadacitinib aces phase III trial

AbbVie’s upadacitinib aces phase III trial

The results were achieved in patients with moderate-to-severe RA who were being treated with methotrexate but whose symptoms were not being controlled.

Latest news

  • Lilly claims another EU okay for Taltz Lilly claims another EU okay for Taltz

    Lilly claims another EU okay for Taltz. The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients. ... The new approval means that Taltz can be used either alone or in combination with methotrexate for PsA patients who

  • AbbVie’s JAK inhibitor upadacitinib clears another phase III trial AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

    Its earlier trials in RA have compared the drug to placebo on top of methotrexate therapy. ... response) after switching from methotrexate therapy, compared to 41% who remained on that regimen.

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Given in combination with methotrexate, the twice-daily administered drug is recommended for adults whose disease hasn’t responded adequately to intensive therapy with conventional or other disease-modifying anti-rheumatic ... Additionally, the drug

  • NICE backs Sanofi's Kevzara for routine NHS use NICE backs Sanofi's Kevzara for routine NHS use

    NICE backs Sanofi's Kevzara for routine NHS use. Recommends the RA treatment in combination with methotrexate. ... Given in combination with methotrexate, the drug maker’s IL-6 inhibitor will be made available for routine use under the NHS for adults

  • Sanofi, Regeneron claim EU approval for eczema drug Dupixent Sanofi, Regeneron claim EU approval for eczema drug Dupixent

    and in trials it has been shown to be effective at both clearing skin and helping patients avoid steroids and topical immunosuppressants such as cyclosporine and methotrexate, which can cause side

More from news
Approximately 2 fully matching, plus 99 partially matching documents found.

Latest appointments

  • Antares appoints David Bergstrom as SVP Antares appoints David Bergstrom as SVP

    The appointments come as the company looks to expand its business after the commercialisation of Otrexup (methotrexate) for arthritis and the advance in development of testosterone replacement therapy Vibex QS T.

  • Former Pfizer VP joins Antares Former Pfizer VP joins Antares

    methotrexate) for arthritis and advance the development of testosterone replacement therapy Vibex QS T. “

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics